Treatment for Pulmonary Fibrosis in PA

What is Pulmonary Fibrosis?

Pulmonary fibrosis is a disease in which the lungs become scarred, causing the intricate passageways inside the lungs to thicken and harden. Hardening of passageways inside the lungs makes it difficult for oxygen to pass through the walls of the tiny air sacs (alveoli) into the bloodstream. The lack of oxygen in the bloodstream leaves sufferers of pulmonary fibrosis short of breath even after periods of prolonged rest. Pulmonary fibrosis is a progressive disease in which sufferers get worse over time, sometimes slowly and other times rapidly. There are, however, new treatment options that help improve the quality of life for those who suffer from the disease. The Lung Institute offers treatment for pulmonary fibrosis in PA.

Quick Facts about Pulmonary Fibrosis:

  • It affects 200,000 people in the United States.
  • The average survival rate is two to three years.
  • There is no known cause for idiopathic pulmonary fibrosis.
  • About 48,000 new cases are diagnosed each year.
  • The disease tends to affect more men than women and typically occurs between ages 50 to 70
  • Pulmonary fibrosis is caused by occupational and environmental factors, a response from medications, autoimmune disorders, infections and genetics.

Occupational Lung Disease in Pennsylvania

Pennsylvania has several reported cases of occupational lung disease, particularly in Pittsburgh. Pittsburgh is known as the “Steel City” because of the city’s historic past with the steel industry. While this has helped build a strong local economy, unfortunately it also comes with negative health repercussions. In fact, the occupational hazards of working in a steel mill can present just as much as a risk as smoking cigarettes, according to a report released by University of Sheffield’s Department of Medicine. Occupational Lung Disease in Pittsburgh is a real problem, and it’s time that sufferers have alternative options other than the traditional treatment methods.

Lung disease is expensive and many workers have to fight to get employers to cover costs. However, expensive medications, or, in more serious cases, a lung transplant, don’t have to be the only option. Minimally invasive stem cell therapy is now an effective treatment for lung disease.

What is Stem Cell Therapy for Pulmonary Fibrosis?

Stem cell therapy harnesses the body’s natural healing capabilities to expedite the healing process. At the Lung Institute, the stem cell procedure is a three day outpatient treatment, where stem cells are extracted from a person’s blood, fat tissue or bone marrow. After the cells have been extracted, they are treated in a lab on site and then reintroduced into the body directly into the damaged tissue areas. Stem cells are how your body heals itself after getting a cut or bruise, however, sometimes this healing process can move more slowly than the disease progresses, like in the case of lung disease. By targeting many stem cells directly onto the damaged tissue, the body has the opportunity to heal itself more quickly. In most cases this results in stopping the progression of the disease or even improved lung function.

At least 70 percent of Lung Institute patients have reported a better quality of life after undergoing stem cell treatment for pulmonary fibrosis. The Lung Institute might be the answer for those seeking treatment for pulmonary fibrosis in Pennsylvania. If you or a loved one suffers from a lung disease like COPD, contact one of our patient coordinators today at (800) 729-3065 to see if you qualify.


* All treatments performed at Lung Institute utilize autologous stem cells, meaning those derived from a patient's own body. No fetal or embryonic stem cells are utilized in Lung Institute's procedures. Lung Institute aims to improve patients' quality of life and help them breathe easier through the use of autologous stem cell therapy. To learn more about how stem cells work for lung disease, click here.

All claims made regarding the efficacy of Lung Institute's treatments as they pertain to pulmonary conditions are based solely on anecdotal support collected by Lung Institute. Individual conditions, treatment and outcomes may vary and are not necessarily indicative of future results. Testimonial participation is voluntary. Lung Institute does not pay for or script patient testimonials.

Under current FDA guidelines and regulations 1271.10 and 1271.15, the Lung Institute complies with all necessary requirements for operation. Any individual who accesses Lung Institute's website for information is encouraged to speak with his or her primary physician for treatment suggestions and conclusive evidence. All information on this site should be used for educational and informational use only.